TACR1 and myeloid sarcoma: Targeting NK-1R also has the potential to ameliorate CNS disorders that are thought to involve sterile inflammation given the presence of substance P immunoreactive glia in MS plaques (Kostyk et al., 1989) and the reported ability of the non-peptide NK-1R antagonist SR140333 to attenuate chronic inflammation associated with mouse models of MS (Reinke et al., 2006).